Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
G. Deplanque, Adrian L. Harris(University of Oxford), Philip H. Jones(University of Cambridge), K Christodoulos(Cancer Research UK), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Sven Wellmann(University Hospital Regensburg), Andrew D. Blann(Birmingham City Hospital), Trivadi S. Ganesan(Churchill Hospital), Denis Talbot(Cancer Research UK)
Cited by 20
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k